#Antimalarial
Antimalarial treatment readiness during malaria elimination PubMed
Antimalarial treatment readiness during malaria elimination
No abstract
dlvr.it
November 20, 2026 at 9:47 PM
he donated to the antimalarial charity in the end. This was more or less a steelman, which nyt would very much like you to ignore
November 20, 2026 at 12:48 AM
I’m a scientist and studied malaria for my PhD… like smallpox it’s an ancient disease and the eradication of smallpox worldwide was only possible bc of the Soviet Union. The current first line antimalarial treatments were also discovered by a scientist working In Revolutionary China
November 19, 2026 at 12:54 AM
Chloroquine and hydroxychloroquine are quinoline-derived antimalarial drugs with similar mechanisms, but hydroxychloroquine is also widely used for autoimmune diseases and generally has a better safety profile.
November 19, 2026 at 9:55 PM
Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese #Plasmodium falciparum #malaria parasites PLOSPathogens
Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese #Plasmodium falciparum #malaria parasites
by Katelyn Vendrely Brenneman, Wesley Wong, Yaye Die Ndiaye, Jonathan T. Smith, Stephen Schaffner, Bassirou Ngom, Karina L. Bellavia, Imran Ullah, Amy Gaye, Djiby Sow, Mame Fama Ndiaye, Mariama Toure, Nogaye Gadiaga, Aita Sene, Awa Bineta Deme, Baba Dieye, Mamadou Samb Yade, Khadim Diongue, Younouss Diedhiou, Jules François Gomis, Mouhamadou Ndiaye, Mamadou Alpha Diallo, Ibrahima Mbaye Ndiaye, Bronwyn MacInnis, Dyann F. Wirth, Daouda Ndiaye, Sarah K. Volkman Drug resistance in #Plasmodium falciparum threatens malaria control and elimination efforts, particularly where sustained chemoprevention and treatment have driven parasite evolution. Senegal has implemented antimalarial strategies for two decades, including sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy and SP plus amodiaquine for seasonal malaria chemoprevention in children. We analyzed whole-genome sequencing (WGS) data from 2,805 monogenomic P. falciparum infections collected from febrile, treatment-seeking patients across Senegal between 2006 and 2022. Wild-type (WT), drug-sensitive alleles at four major resistance loci (Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps) were rare, while resistance-associated variants, including Pfcrt K76T, the canonical Pfdhfr triple mutant (N51I, C59R, S108N), and Pfdhps A437G, predominated. To define how these genotypes shape drug response and parasite fitness, we cultured 33 clinical isolates representing 26 common combined haplotypes, which together accounted for 63.9% of infections in the WGS dataset. Multivariable mixed-effects models revealed drug- and background-dependent effects. Relative to the Pfcrt WT, the CVIET background increased monodesethyl-amodiaquine EC50 approximately 1.4-fold; adding N326S or I356T produced cumulative increases of approximately 2.6-fold and 3.2-fold, respectively. The Pfdhfr triple mutant increased pyrimethamine EC50 approximately 2,196-fold relative to Pfdhfr WT. For sulfadoxine, Pfdhps A437G was associated with an approximately 463,000-fold increase in EC50 relative to WT, while Pfdhps S436A had little effect. Pairwise competitive growth outcomes analyzed with a Bradley-Terry model showed reduced competitive ability for Pfcrt CVIET, partially rescued by Pfmdr1 Y184F; Pfdhps S436A increased whereas A613S reduced competitive ability. These findings reveal resistance-fitness trade-offs that may shape P. falciparum evolution as antimalarial policies change across Africa.
dlvr.it
November 22, 2026 at 4:49 PM
Salim, Paloque, Reyser, Nardella, Augereau, Luo, Britton, Mergny, Gervais, Benoit-Vical, Gomez: Selective Disruption of Plasmodium falciparum mitochondrial DNA via G-Quadruplex-Binding Ligand RHPS4 Provides a Novel Antimalarial Strategy https://hal.science/hal-05528485v1 [sdv]
November 19, 2026 at 3:01 AM
Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese #Plasmodium falciparum #malaria parasites PLOSPathogens
Genotype-phenotype investigation of evolving mutations associated with antimalarial resistance among Senegalese #Plasmodium falciparum #malaria parasites
by Katelyn Vendrely Brenneman, Wesley Wong, Yaye Die Ndiaye, Jonathan T. Smith, Stephen Schaffner, Bassirou Ngom, Karina L. Bellavia, Imran Ullah, Amy Gaye, Djiby Sow, Mame Fama Ndiaye, Mariama Toure, Nogaye Gadiaga, Aita Sene, Awa Bineta Deme, Baba Dieye, Mamadou Samb Yade, Khadim Diongue, Younouss Diedhiou, Jules François Gomis, Mouhamadou Ndiaye, Mamadou Alpha Diallo, Ibrahima Mbaye Ndiaye, Bronwyn MacInnis, Dyann F. Wirth, Daouda Ndiaye, Sarah K. Volkman Drug resistance in #Plasmodium falciparum threatens malaria control and elimination efforts, particularly where sustained chemoprevention and treatment have driven parasite evolution. Senegal has implemented antimalarial strategies for two decades, including sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy and SP plus amodiaquine for seasonal malaria chemoprevention in children. We analyzed whole-genome sequencing (WGS) data from 2,805 monogenomic P. falciparum infections collected from febrile, treatment-seeking patients across Senegal between 2006 and 2022. Wild-type (WT), drug-sensitive alleles at four major resistance loci (Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps) were rare, while resistance-associated variants, including Pfcrt K76T, the canonical Pfdhfr triple mutant (N51I, C59R, S108N), and Pfdhps A437G, predominated. To define how these genotypes shape drug response and parasite fitness, we cultured 33 clinical isolates representing 26 common combined haplotypes, which together accounted for 63.9% of infections in the WGS dataset. Multivariable mixed-effects models revealed drug- and background-dependent effects. Relative to the Pfcrt WT, the CVIET background increased monodesethyl-amodiaquine EC50 approximately 1.4-fold; adding N326S or I356T produced cumulative increases of approximately 2.6-fold and 3.2-fold, respectively. The Pfdhfr triple mutant increased pyrimethamine EC50 approximately 2,196-fold relative to Pfdhfr WT. For sulfadoxine, Pfdhps A437G was associated with an approximately 463,000-fold increase in EC50 relative to WT, while Pfdhps S436A had little effect. Pairwise competitive growth outcomes analyzed with a Bradley-Terry model showed reduced competitive ability for Pfcrt CVIET, partially rescued by Pfmdr1 Y184F; Pfdhps S436A increased whereas A613S reduced competitive ability. These findings reveal resistance-fitness trade-offs that may shape P. falciparum evolution as antimalarial policies change across Africa.
dlvr.it
November 21, 2026 at 9:48 AM
During #WAAW26, we join our partners across the global #malaria community to sound the alarm on antimalarial drug resistance.

Together, we're working to extend the useful life of existing medicines while developing next-generation interventions as the parasite continues to evolve.
November 18, 2026 at 12:10 PM
Antileishmanial and antimalarial activities of synthetic marine endoperoxides pubmed.ncbi.nlm.nih.gov/43019854/
November 13, 2026 at 12:30 PM
Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins bioRxivpreprint
Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins
Determining the origin of recurrent Plasmodium vivax infections is critical for quantifying the public health burden of the hypnozoite reservoir, understanding transmission potential, and evaluating anti-relapse antimalarial efficacy. In Ethiopia, P. vivax is a major contributor to malaria burden, but the relative contribution of relapse to recurrent infections remains poorly quantified. We performed microhaplotype genotyping using a panel of 93 genome-wide markers and applied a probabilistic recurrence classification framework to recurrent P. vivax samples collected in two Ethiopian radical cure trials (IMPROV and OPRA). Genotyping was conducted on parasite isolates collected at enrolment and subsequent recurrences, with participants monitored over a 12-month follow-up period (IMPROV: 604 samples from 444 participants; OPRA: 621 samples from 342 participants). Recurrent infections were classified using a Bayesian hierarchical model implemented in Pv3Rs, which estimated marginal posterior probabilities of relapse, reinfection, or recrudescence based on genotyping data and background population dynamics. Priors were structured across biologically motivated time windows reflecting the natural history of P. vivax infection in Ethiopia and anticipated drug efficacy. Recurrences with a probability of relapse (p(L)) [≥] 0.75 were classified as relapses. In the absence of primaquine, probable relapse was the dominant classification for primary recurrent infections in both trials (75.5%; 102/135) and for consecutive recurrent infections within individuals (75.2%; 204/271). Primaquine substantially reduced the proportion of participants experiencing recurrent infections attributable to probable relapse, from 57.3% to 1.7% in IMPROV and from 60.2% to 9.5% in OPRA. Polyclonal infection at enrolment was independently associated with increased odds of recurrence and a higher rate of probable relapse in OPRA, with a consistent but non-significant trend observed in IMPROV. These findings provide direct molecular evidence that the hypnozoite reservoir is the dominant driver of recurrent P. vivax infections in Ethiopia in the absence of radical cure. The marked reduction in probable relapse following primaquine treatment highlights the critical importance of expanding access to safe and effective radical cure strategies in Ethiopia and other comparable high-transmission settings.
dlvr.it
November 15, 2026 at 12:44 AM
Multiple adaptive trajectories shape antimalarial resistance evolution in Ethiopian Plasmodium falciparum bioRxivpreprint
Multiple adaptive trajectories shape antimalarial resistance evolution in Ethiopian Plasmodium falciparum
Plasmodium falciparum malaria continues to impose a substantial public health burden across sub-Saharan Africa, with Ethiopia experiencing a recent resurgence in malaria cases. We analysed whole genome data from 120 P. falciparum isolates collected in 2024 across five ecologically and epidemiologically diverse transmission settings in Ethiopia and placed these in the context of 1,220 publicly available genomes. Parasite populations were highly structured within Ethiopia, while Horn of Africa isolates formed a genetically distinct regional cluster relative to East and West African populations. We identified evidence of recent positive selection surrounding the artemisinin resistance associated PfK13 R622I variant and detected co-occurrence with Pfcrt mutations together with recurrent selection signals at genes within the PfK13-associated haemoglobin endocytosis pathway, including Pfmca2, Pfkic7, Pfkic8 and Pfkic9. We further observed the emergence of the PfPX1 D384A-PIN haplotype, with shared identity-by-descent linking Ethiopian and Ugandan carriers, supporting a recent introduction followed by local selection. Widespread Pfhrp2/3 deletions occurred on diverse genetic backgrounds. Together, these findings reveal a complex adaptive landscape shaped by antimalarial and diagnostic selection pressures and suggest that parasite evolution in the Horn of Africa proceeds through multiple adaptive trajectories, rather than through the spread of a single dominant lineage.
dlvr.it
November 12, 2026 at 9:17 AM
Multiple adaptive trajectories shape antimalarial resistance evolution in Ethiopian Plasmodium falciparum https://www.biorxiv.org/content/10.64898/2026.11.09.764565v1
November 11, 2026 at 2:15 AM
Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins bioRxivpreprint
Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins
Determining the origin of recurrent Plasmodium vivax infections is critical for quantifying the public health burden of the hypnozoite reservoir, understanding transmission potential, and evaluating anti-relapse antimalarial efficacy. In Ethiopia, P. vivax is a major contributor to malaria burden, but the relative contribution of relapse to recurrent infections remains poorly quantified. We performed microhaplotype genotyping using a panel of 93 genome-wide markers and applied a probabilistic recurrence classification framework to recurrent P. vivax samples collected in two Ethiopian radical cure trials (IMPROV and OPRA). Genotyping was conducted on parasite isolates collected at enrolment and subsequent recurrences, with participants monitored over a 12-month follow-up period (IMPROV: 604 samples from 444 participants; OPRA: 621 samples from 342 participants). Recurrent infections were classified using a Bayesian hierarchical model implemented in Pv3Rs, which estimated marginal posterior probabilities of relapse, reinfection, or recrudescence based on genotyping data and background population dynamics. Priors were structured across biologically motivated time windows reflecting the natural history of P. vivax infection in Ethiopia and anticipated drug efficacy. Recurrences with a probability of relapse (p(L)) [≥] 0.75 were classified as relapses. In the absence of primaquine, probable relapse was the dominant classification for primary recurrent infections in both trials (75.5%; 102/135) and for consecutive recurrent infections within individuals (75.2%; 204/271). Primaquine substantially reduced the proportion of participants experiencing recurrent infections attributable to probable relapse, from 57.3% to 1.7% in IMPROV and from 60.2% to 9.5% in OPRA. Polyclonal infection at enrolment was independently associated with increased odds of recurrence and a higher rate of probable relapse in OPRA, with a consistent but non-significant trend observed in IMPROV. These findings provide direct molecular evidence that the hypnozoite reservoir is the dominant driver of recurrent P. vivax infections in Ethiopia in the absence of radical cure. The marked reduction in probable relapse following primaquine treatment highlights the critical importance of expanding access to safe and effective radical cure strategies in Ethiopia and other comparable high-transmission settings.
dlvr.it
November 13, 2026 at 5:43 PM
Multiple adaptive trajectories shape antimalarial resistance evolution in Ethiopian Plasmodium falciparum bioRxivpreprint
Multiple adaptive trajectories shape antimalarial resistance evolution in Ethiopian Plasmodium falciparum
Plasmodium falciparum malaria continues to impose a substantial public health burden across sub-Saharan Africa, with Ethiopia experiencing a recent resurgence in malaria cases. We analysed whole genome data from 120 P. falciparum isolates collected in 2024 across five ecologically and epidemiologically diverse transmission settings in Ethiopia and placed these in the context of 1,220 publicly available genomes. Parasite populations were highly structured within Ethiopia, while Horn of Africa isolates formed a genetically distinct regional cluster relative to East and West African populations. We identified evidence of recent positive selection surrounding the artemisinin resistance associated PfK13 R622I variant and detected co-occurrence with Pfcrt mutations together with recurrent selection signals at genes within the PfK13-associated haemoglobin endocytosis pathway, including Pfmca2, Pfkic7, Pfkic8 and Pfkic9. We further observed the emergence of the PfPX1 D384A-PIN haplotype, with shared identity-by-descent linking Ethiopian and Ugandan carriers, supporting a recent introduction followed by local selection. Widespread Pfhrp2/3 deletions occurred on diverse genetic backgrounds. Together, these findings reveal a complex adaptive landscape shaped by antimalarial and diagnostic selection pressures and suggest that parasite evolution in the Horn of Africa proceeds through multiple adaptive trajectories, rather than through the spread of a single dominant lineage.
dlvr.it
November 11, 2026 at 2:16 AM
this is a resolute and profitable idea the only reason I’m not getting a grant for it is because Big Antimalarial is silencing me
November 8, 2026 at 9:53 AM
Interested in the current state of antimalarial drug resistance in Africa?

Join the @isntd.org & #MARCSEAfrica webinar on 24 November (3 PM CET/4 PM CAT) to find out all about it.

More information & registration➡️ tinyurl.com/yxexuyxv

@globalhealthedctp3.bsky.social #AMDR #AMR #WAAW2026
November 9, 2026 at 7:59 AM
Check out our most recent efforts (and cover art!) in @orgbiomolchem.rsc.org on how we leveraged chemical halogenation to transform premarineosin A into an even more potent antimalarial. Many thanks to our collaborators and teammates for their hard work! 👩‍🔬
📢Our latest issue is now online!

🔓Check out the #OpenAccess paper behind the cover from David H. Sherman, @pereiralab.bsky.social & co. @umich.edu describing the chemoselective halogenation of premarineosin A for next-generation antimalarial development #orgchem #medchem

doi.org/10.1039/d6ob...
November 5, 2026 at 8:44 PM
Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial PubMed
Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial
BACKGROUND: Ganaplacide plus lumefantrine solid dispersion formulation (SDF) is a novel antimalarial combination shown to be effective and well tolerated in adults, adolescents, and children with uncomplicated Plasmodium falciparum malaria. Here, we aimed to assess food effects on drug exposure and non-inferiority of ganaplacide plus lumefantrine SDF to artemether-lumefantrine.
dlvr.it
November 7, 2026 at 6:27 PM
On 4 Nov, a Puskesmas manager reported that they had no antimalarial treatment or malaria rapid tests left. We replenished Kawan Sehat agents’ supplies & worked with public health centers in East Sumba.
https://fairfuturefoundation.org/kawan-sehat-medicine-restocking-east-sumba/
#KawanSehat
Keeping village care within reach in East Sumba
At Kawangu and Kataka, medicine supplies, health cards and case discussions support the Kawan Sehat agents caring for remote communities.
fairfuturefoundation.org
November 4, 2026 at 4:00 PM
Discovery of P1-P2 depeptidized boronic acid based Plasmodium falciparum SUB1 inhibitor bioRxivpreprint
Discovery of P1-P2 depeptidized boronic acid based Plasmodium falciparum SUB1 inhibitor
The Plasmodium falciparum subtilisin-like serine protease 1 (PfSUB1) is an essential enzyme required for parasite egress from host red blood cells and represents a promising target for antimalarial drugs. Peptidic boronic acids are potent reported PfSUB1 inhibitors, however their drug-likeness is limited by their pronounced peptidic character. Based on molecular docking studies using peptidic boronic acids, we designed a series of partially depeptidized PfSUB1 inhibitors by replacing the P1-P2 dipeptide fragment with a 3-aminomethylphenylboronic acid core. Structure-activity relationship (SAR) investigations targeting interaction with active-site residue Lys138 revealed that introducing a meta-carboxylate group (compound 3a) markedly enhanced inhibitory activity, yielding a low-nanomolar PfSUB1 inhibitor (IC50= 10.2 nM). Bioisosteric replacement of the carboxylic acid demonstrated that an N-acylsulfonamide group (compound 4k) retained high enzymatic potency (IC50= 13.5 nM)). In cellular assays against blood-stage P. falciparum (3D7 strain), the leading depeptidized boronic acids exhibited growth inhibition with values in the low-micromolar range suggesting that further structural modifications are needed to enhance membrane permeability across host and parasite membranes to reach exonemes prior to egress. Overall, this study validates the P1-P2 depeptidization of boronic acid scaffolds and provides key SAR insights for the rational design of non-peptidic PfSUB1-targeted antimalarials.
dlvr.it
November 5, 2026 at 1:10 AM
Discovery of P1-P2 depeptidized boronic acid based Plasmodium falciparum SUB1 inhibitor bioRxivpreprint
Discovery of P1-P2 depeptidized boronic acid based Plasmodium falciparum SUB1 inhibitor
The Plasmodium falciparum subtilisin-like serine protease 1 (PfSUB1) is an essential enzyme required for parasite egress from host red blood cells and represents a promising target for antimalarial drugs. Peptidic boronic acids are potent reported PfSUB1 inhibitors, however their drug-likeness is limited by their pronounced peptidic character. Based on molecular docking studies using peptidic boronic acids, we designed a series of partially depeptidized PfSUB1 inhibitors by replacing the P1-P2 dipeptide fragment with a 3-aminomethylphenylboronic acid core. Structure-activity relationship (SAR) investigations targeting interaction with active-site residue Lys138 revealed that introducing a meta-carboxylate group (compound 3a) markedly enhanced inhibitory activity, yielding a low-nanomolar PfSUB1 inhibitor (IC50= 10.2 nM). Bioisosteric replacement of the carboxylic acid demonstrated that an N-acylsulfonamide group (compound 4k) retained high enzymatic potency (IC50= 13.5 nM)). In cellular assays against blood-stage P. falciparum (3D7 strain), the leading depeptidized boronic acids exhibited growth inhibition with values in the low-micromolar range suggesting that further structural modifications are needed to enhance membrane permeability across host and parasite membranes to reach exonemes prior to egress. Overall, this study validates the P1-P2 depeptidization of boronic acid scaffolds and provides key SAR insights for the rational design of non-peptidic PfSUB1-targeted antimalarials.
dlvr.it
November 3, 2026 at 6:10 PM
Clinicians must prepare for changing malaria treatment landscapes by prioritizing surveillance, drug quality assurance, and next-generation antimalarial strategies in East Africa.

https://news.gmj.ge/briefs/what-clinicians-and-health-systems-need-to-know-about-artemisinin-resistance-in-east-africa/
What Clinicians and Health Systems Need to Know About Artemisinin Resistance in East Africa
Clinicians must prepare for changing malaria treatment landscapes by prioritizing surveillance, drug quality assurance, and next-generation antimalarial strategies in East Africa.
news.gmj.ge
November 2, 2026 at 7:27 AM
Upcoming seminar by Julien ROBERT-PAGANIN,: Investigating Plasmodium myosins to identify antimalarial targets at Institut Cochin, Thursday 12 November 2026. More info
October 30, 2026 at 12:09 PM